Biomarker Analysis Services for Urticaria
Ace Therapeutics offers specialized biomarker analysis services exclusively focused on supporting drug discovery and preclinical development for Urticaria research. Our comprehensive biomarker panel is designed to illuminate the complex pathophysiology of Urticaria, providing actionable insights for therapeutic innovation. Please note that all our services are dedicated to research and development applications only and do not include clinical diagnostic services.
Effective therapeutic intervention for Urticaria begins with the robust discovery and identification of relevant biomarkers. At Ace Therapeutics, our biomarker discovery services are integral to the drug development process, enabling the identification of molecular targets that drive disease mechanisms. We employ systematic screening and validation processes, including high-throughput assays and bioinformatic analyses, to uncover and confirm candidate biomarkers with potential utility in preclinical research. This rigorous approach ensures that each identified biomarker is thoroughly characterized for its relevance to Urticaria-related pathways.
Multi Omics: Our multi-omics approach leverages advanced genomics, transcriptomics, proteomics, and metabolomics technologies to provide a holistic understanding of biological systems underlying Urticaria. By integrating data from DNA, RNA, protein, and metabolite analyses, we enable comprehensive profiling of disease-associated molecular networks. This multi-layered strategy facilitates the identification of biomarkers across diverse biological matrices and supports the elucidation of key disease pathways, such as immune cell recruitment, cytokine signaling, and inflammatory mediator production, all of which are pertinent to Urticaria pathogenesis.
Candidate Validation: Candidate biomarker validation at Ace Therapeutics involves a suite of strategies designed to establish the association of each marker with Urticaria pathophysiology. Preliminary screening includes quantitative and qualitative analyses in relevant preclinical models, followed by orthogonal validation using complementary techniques. Criteria for prioritizing promising candidates include biological plausibility, reproducibility across sample sets, specificity to Urticaria-related mechanisms, and technical feasibility for assay development. This systematic process ensures only the most relevant research targets advance for further study.
Diverse Technological Platforms: We offer custom biomarker assay development tailored to the unique requirements of Urticaria research. Our technological platforms are adaptable and include immunoassay systems, mass spectrometry, flow cytometry, molecular diagnostics, and advanced histopathology and imaging solutions. Each platform is selected and optimized based on the specific analytical needs of the biomarker and the biological matrix under investigation.
Immunoassays: We utilize ELISA, chemiluminescent assays, and multiplex immunoassays for sensitive and specific quantification of cytokines, chemokines, and other protein biomarkers relevant to Urticaria.
Mass Spectrometry: Our LC-MS/MS platforms enable precise, high-throughput quantification and characterization of proteins, peptides, and metabolites implicated in disease pathways.
Flow Cytometry: We employ flow cytometry for immunophenotyping and quantitative analysis of cell surface and intracellular biomarkers in immune cell populations.
Molecular Diagnostics: PCR-based and next-generation sequencing methods are used for the detection and quantification of gene expression and genetic variants associated with Urticaria.
Histopathology And Imaging: Advanced tissue imaging and digital pathology techniques are applied for spatial localization and quantification of biomarkers in tissue sections.
Rigorous Method Validation: All analytical methods undergo rigorous validation in accordance with established guidelines to ensure accuracy, precision, sensitivity, specificity, and reproducibility. Performance characteristics such as linearity, limit of detection, dynamic range, and inter/intra-assay variability are systematically evaluated. Comprehensive quality control measures are implemented throughout the analytical workflow to guarantee data integrity and reliability for preclinical research applications.
Our quantitative analysis capabilities encompass absolute and relative quantification of biomarker levels in diverse biological matrices. We employ validated calibration standards, internal controls, and robust statistical methodologies to ensure accurate measurement and interpretation of biomarker data. These quantitative insights are essential for understanding disease mechanisms and informing preclinical decision-making.
Sample Analysis: Ace Therapeutics processes a wide range of sample types, including serum, plasma, tissue homogenates, and cell lysates, with standardized protocols to maximize analyte stability and recovery. Each sample is subjected to stringent quality control checks, and all analytical procedures are performed according to validated protocols to ensure consistency and reproducibility. Our sample handling workflows are optimized for both single-plex and multiplex analyses, supporting comprehensive biomarker profiling.
High Throughput Capabilities: Our high-throughput analytical platforms, including multiplex immunoassays and automated LC-MS/MS systems, enable efficient analysis of large sample cohorts. These technologies facilitate the simultaneous quantification of multiple biomarkers from limited sample volumes, conserving valuable preclinical material and accelerating project timelines. Automated data acquisition and processing further enhance throughput and data quality.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| C-C motif chemokine ligand 17 (CCL17) | C-C motif chemokine ligand 17 (CCL17), also known as thymus and activation-regulated chemokine (TARC), is a member of the CC chemokine family. It is primarily produced by dendritic cells, endothelial cells, and keratinocytes. CCL17 functions as a chemoattractant, mainly recruiting T lymphocytes that express the CCR4 receptor, particularly Th2-type CD4+ T cells. Through its interaction with CCR4, CCL17 plays a significant role in the regulation of immune responses, including the trafficking of T cells to sites of inflammation and the modulation of allergic and inflammatory processes. Its expression is upregulated in response to pro-inflammatory cytokines such as TNF-α and IL-4. | CCL17 has been studied as a biomarker in various immune-mediated and inflammatory conditions. Elevated levels of CCL17 in serum or other biological fluids have been reported in diseases such as atopic dermatitis, asthma, and certain autoimmune disorders. Measurement of CCL17 concentrations has been used to assess disease activity, monitor therapeutic response, and differentiate between specific inflammatory conditions. Its application as a biomarker is based on its association with Th2-driven immune responses and its increased expression during active disease states. |
| C-X-C motif chemokine ligand 8 (CXCL8) | C-X-C motif chemokine ligand 8 (CXCL8), also known as interleukin-8 (IL-8), is a chemokine produced by various cell types, including macrophages, epithelial cells, and endothelial cells, in response to inflammatory stimuli. CXCL8 primarily functions as a chemoattractant for neutrophils, guiding their migration to sites of infection or tissue injury. It exerts its effects by binding to the CXCR1 and CXCR2 receptors on neutrophils and other immune cells, promoting chemotaxis, degranulation, and respiratory burst. CXCL8 also contributes to angiogenesis and plays a role in modulating the inflammatory response by influencing the activity and recruitment of additional immune cells. | CXCL8 has been studied as a biomarker in a variety of clinical contexts, particularly for its association with inflammatory and infectious diseases. Elevated levels of CXCL8 in biological fluids such as serum, plasma, or bronchoalveolar lavage fluid have been reported in conditions including sepsis, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and certain cancers. Measurement of CXCL8 concentrations can provide information about the presence and degree of inflammation, disease activity, or prognosis in these settings. |
| Fc epsilon receptor Ia (FCER1A) | Fc epsilon receptor Ia (FCER1A) encodes the alpha subunit of the high-affinity receptor for immunoglobulin E (IgE), known as FcεRI. This receptor is primarily expressed on the surface of mast cells and basophils. The alpha subunit binds to the Fc region of IgE antibodies with high affinity, facilitating the sensitization of these cells to allergens. Upon subsequent exposure to an allergen, cross-linking of the IgE bound to FcεRI triggers cellular activation, leading to the release of inflammatory mediators such as histamine, cytokines, and chemokines. This process is central to the initiation and propagation of immediate hypersensitivity (allergic) reactions. | FCER1A has been utilized as a biomarker in studies related to allergic diseases, including asthma, atopic dermatitis, and allergic rhinitis. Its expression levels, particularly on peripheral blood basophils and dendritic cells, have been measured to assess allergic sensitization and disease activity. FCER1A has also been investigated as a marker for monitoring the effects of allergen immunotherapy and for distinguishing between atopic and non-atopic individuals in research settings. |
| cellular communication network factor 1 (CCN1) | Cellular communication network factor 1 (CCN1), also known as cysteine-rich angiogenic inducer 61 (CYR61), is a matricellular protein belonging to the CCN family. It plays a key role in modulating cell adhesion, migration, proliferation, and differentiation through interactions with integrins and heparan sulfate proteoglycans. CCN1 is involved in processes such as angiogenesis, wound healing, inflammation, and tissue remodeling. It influences extracellular matrix production and mediates cellular responses to growth factors and cytokines. CCN1 is expressed in various tissues and is dynamically regulated during development and in response to injury. | CCN1 has been investigated as a biomarker in several pathological conditions, including cancer, cardiovascular diseases, and fibrotic disorders. Altered expression levels of CCN1 have been reported in tumor tissues and serum samples from patients with certain malignancies, such as breast and prostate cancer. In cardiovascular research, CCN1 expression has been studied in the context of atherosclerosis and myocardial infarction. Additionally, increased CCN1 levels have been associated with fibrotic diseases, including liver and lung fibrosis. Its measurement in tissue or circulating fluids has been explored for potential use in disease diagnosis, prognosis, and monitoring. |
| histamine receptor H4 (HRH4) | Histamine receptor H4 (HRH4) is a member of the G protein-coupled receptor family that binds histamine as its endogenous ligand. HRH4 is primarily expressed in cells of the immune system, including eosinophils, mast cells, dendritic cells, and T lymphocytes. Upon activation by histamine, HRH4 mediates chemotaxis and calcium mobilization in these immune cells, contributing to the regulation of inflammatory and immune responses. The receptor is involved in modulating cytokine production, cell migration, and the recruitment of immune cells to sites of inflammation. HRH4 is also expressed in tissues such as the bone marrow, spleen, and gastrointestinal tract, suggesting a broader role in immune surveillance and homeostasis. | HRH4 expression and function have been studied as potential indicators in various inflammatory and immune-mediated conditions. Altered HRH4 levels have been reported in diseases such as allergic rhinitis, asthma, atopic dermatitis, and certain autoimmune disorders. Additionally, HRH4 has been investigated in the context of some cancers, particularly regarding its role in tumor-associated inflammation and immune cell infiltration. Its expression profile in immune cells and tissues is used in research to assess disease activity, immune status, and the potential response to therapies targeting the histamine pathway. |
| interleukin 13 (IL13) | Interleukin 13 (IL13) is a cytokine primarily produced by activated Th2-type CD4+ T lymphocytes, as well as other immune cells such as mast cells and basophils. IL13 plays a central role in the regulation of immune responses, particularly those associated with allergic inflammation and defense against parasitic infections. It modulates the function of various cell types, including B cells, epithelial cells, fibroblasts, and macrophages. IL13 promotes IgE class switching in B cells, induces mucus production in airway epithelial cells, and contributes to tissue remodeling and fibrosis through its effects on fibroblasts. It also suppresses pro-inflammatory cytokine production by macrophages and is involved in the regulation of eosinophil recruitment. IL13 shares several overlapping functions with interleukin 4 (IL4), partly due to the use of shared receptor components. | IL13 has been investigated as a biomarker in a range of conditions characterized by type 2 immune responses. Elevated levels of IL13 in serum, plasma, or tissue samples have been associated with allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis. In these contexts, IL13 levels have been used to reflect disease activity, severity, or response to therapy. Additionally, increased IL13 expression has been reported in certain fibrotic disorders and some cancers, where it may indicate underlying inflammatory or remodeling processes. Measurement of IL13, alone or in combination with other cytokines, has been utilized in research and clinical studies to aid in disease characterization and monitoring. |
| interleukin 4 (IL4) | Interleukin 4 (IL4) is a cytokine produced primarily by activated T helper 2 (Th2) cells, mast cells, and basophils. It plays a central role in the regulation of immune responses, particularly in the differentiation of naïve CD4+ T cells into Th2 cells. IL4 promotes the proliferation and differentiation of B cells and stimulates immunoglobulin class switching to IgE and IgG1 isotypes. It also inhibits the production of pro-inflammatory cytokines and the differentiation of Th1 cells. Through these actions, IL4 contributes to the regulation of humoral immunity, allergic responses, and the suppression of certain inflammatory processes. | IL4 has been utilized as a biomarker to assess Th2-mediated immune responses. Elevated IL4 levels have been detected in various allergic conditions, such as asthma, atopic dermatitis, and allergic rhinitis. Measurement of IL4 concentrations in serum, plasma, or local tissues can provide information about the presence and extent of Th2-driven inflammation. Additionally, IL4 has been investigated as a marker in autoimmune diseases, some cancers, and parasitic infections, where altered IL4 expression may reflect underlying immunological changes. |
| interleukin 5 (IL5) | Interleukin 5 (IL5) is a cytokine primarily produced by activated Th2 lymphocytes, mast cells, and eosinophils. It plays a central role in the regulation of eosinophil growth, differentiation, activation, and survival. IL5 acts through the IL5 receptor, which is predominantly expressed on eosinophils and basophils, promoting their proliferation and functional responses. By influencing eosinophil biology, IL5 is involved in the immune response to parasitic infections and contributes to the pathogenesis of allergic inflammation. | IL5 has been measured in biological fluids such as blood and sputum to assess eosinophilic inflammation, particularly in allergic diseases like asthma and eosinophilic disorders. Elevated IL5 levels have been associated with disease activity and severity in conditions characterized by increased eosinophil involvement. Quantification of IL5 can aid in the evaluation of inflammatory status and may inform therapeutic decisions in diseases where eosinophils play a prominent role. |
| interleukin 6 (IL6) | Interleukin 6 (IL6) is a multifunctional cytokine that plays a central role in the regulation of immune and inflammatory responses. It is produced by a variety of cell types, including T cells, B cells, macrophages, fibroblasts, and endothelial cells, in response to infections, tissue injury, and other stimuli. IL6 functions by binding to its receptor complex, leading to activation of the JAK/STAT signaling pathway. This cytokine is involved in the differentiation of B cells into antibody-producing cells, the stimulation of acute phase protein synthesis in the liver, and the regulation of hematopoiesis. Additionally, IL6 contributes to the transition from innate to adaptive immunity and modulates metabolic, regenerative, and neural processes. | IL6 is measured in biological fluids such as serum, plasma, and cerebrospinal fluid as an indicator of inflammation and immune activation. Elevated IL6 levels have been associated with a variety of clinical conditions, including infectious diseases, autoimmune disorders, and certain cancers. It is frequently used as a biomarker to assess the presence and severity of systemic inflammation, to monitor disease progression, and to evaluate response to therapy in contexts such as sepsis, rheumatoid arthritis, and COVID-19. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF) is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as other immune and non-immune cells. It plays a central role in the regulation of immune responses, inflammation, cell proliferation, differentiation, and apoptosis. TNF exerts its effects by binding to two distinct receptors, TNFR1 and TNFR2, initiating intracellular signaling cascades that can result in the activation of transcription factors such as NF-κB and the induction of inflammatory gene expression. TNF is also involved in the pathogenesis of various diseases characterized by chronic inflammation. | TNF is measured in biological fluids such as serum, plasma, or synovial fluid as an indicator of inflammatory activity. Its levels have been used to assess disease activity and monitor therapeutic response in conditions such as rheumatoid arthritis, inflammatory bowel disease, sepsis, and other autoimmune or inflammatory disorders. TNF concentrations may also be evaluated in clinical studies to investigate the efficacy of anti-TNF therapies. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services for Urticaria leverage advanced analytical platforms and scientific expertise to support exploratory and preclinical research. All biomarkers discussed herein are research targets only and are provided for investigational purposes; we do not claim any biomarker as validated or mandatory for Urticaria research. Our focus is strictly on the preclinical stages of drug discovery, and our approach maintains the highest standards of scientific objectivity.
We invite you to engage with Ace Therapeutics for collaborative discussions on exploratory biomarker research in Urticaria. Our team is dedicated to advancing scientific knowledge through objective, preclinical research partnerships, and we look forward to exchanging ideas and expertise to drive innovation in this field.
Make Order
Experimental Scheme
Implementation
Conclusion
